GB1581472A - Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them - Google Patents
Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- GB1581472A GB1581472A GB1459877A GB1459877A GB1581472A GB 1581472 A GB1581472 A GB 1581472A GB 1459877 A GB1459877 A GB 1459877A GB 1459877 A GB1459877 A GB 1459877A GB 1581472 A GB1581472 A GB 1581472A
- Authority
- GB
- United Kingdom
- Prior art keywords
- plasminogen
- fibrin
- compounds
- solution
- plasminogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000013566 Plasminogen Human genes 0.000 title claims description 130
- 108010051456 Plasminogen Proteins 0.000 title claims description 130
- 150000001875 compounds Chemical class 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000243 solution Substances 0.000 claims description 69
- 102000009123 Fibrin Human genes 0.000 claims description 67
- 108010073385 Fibrin Proteins 0.000 claims description 67
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 67
- 229950003499 fibrin Drugs 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 66
- 229940012957 plasmin Drugs 0.000 claims description 24
- 230000009089 cytolysis Effects 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 108010087750 lysyl-plasminogen Proteins 0.000 claims description 15
- 230000003169 placental effect Effects 0.000 claims description 15
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 15
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 14
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 229960005356 urokinase Drugs 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- 108010023197 Streptokinase Proteins 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 229960005202 streptokinase Drugs 0.000 claims description 9
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 8
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 8
- 229940127126 plasminogen activator Drugs 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 108010033276 Peptide Fragments Proteins 0.000 claims description 5
- 102000007079 Peptide Fragments Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 4
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000008366 buffered solution Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 108010057207 plasminogen-valine Proteins 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 7
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000963 caseinolytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000058 esterolytic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000896 plasminic effect Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7610143A FR2347048A2 (fr) | 1976-04-07 | 1976-04-07 | Compositions constituees par des composes du type plasminogene, notamment d'origine placentaire, procede d'obtention des ces compositions, et medicaments contenant ces compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1581472A true GB1581472A (en) | 1980-12-17 |
Family
ID=9171508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1459877A Expired GB1581472A (en) | 1976-04-07 | 1977-04-06 | Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS52151711A (enrdf_load_stackoverflow) |
| BE (1) | BE853350R (enrdf_load_stackoverflow) |
| DE (1) | DE2715748C3 (enrdf_load_stackoverflow) |
| FR (1) | FR2347048A2 (enrdf_load_stackoverflow) |
| GB (1) | GB1581472A (enrdf_load_stackoverflow) |
| NL (1) | NL7703738A (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55153592A (en) * | 1979-05-17 | 1980-11-29 | Green Cross Corp:The | Preparation of plasminogen |
| ES8106836A2 (es) * | 1979-07-27 | 1981-10-01 | Fabre Sa Pierre | Procedimiento de obtencion de un activador del plasminogeno |
| AU6642281A (en) * | 1979-11-13 | 1981-06-03 | Husain, S.S. | Isolation of plasminogen activators useful as therapeutic anddiagnostic agents |
| JPS5716824A (en) * | 1980-07-03 | 1982-01-28 | Green Cross Corp:The | Plasminogen pharmaceutical and stabilizing method thereof |
| GB2068002B (en) * | 1980-01-25 | 1983-06-29 | Green Cross Corp | Plasminogen preparation and their production |
| DE3119157A1 (de) * | 1981-05-14 | 1982-12-09 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von und danach hergestelltes plasminogen |
| JPH0725696B2 (ja) * | 1986-05-29 | 1995-03-22 | 株式会社ミドリ十字 | プラスミノ−ゲンの安定化方法 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (enrdf_load_stackoverflow) * | 1973-12-18 | 1977-04-22 | Choay Sa |
-
1976
- 1976-04-07 FR FR7610143A patent/FR2347048A2/fr active Granted
-
1977
- 1977-04-05 NL NL7703738A patent/NL7703738A/xx not_active Application Discontinuation
- 1977-04-06 GB GB1459877A patent/GB1581472A/en not_active Expired
- 1977-04-07 DE DE19772715748 patent/DE2715748C3/de not_active Expired
- 1977-04-07 JP JP3993377A patent/JPS52151711A/ja active Granted
- 1977-04-07 BE BE176506A patent/BE853350R/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2715748B2 (de) | 1981-03-19 |
| FR2347048A2 (fr) | 1977-11-04 |
| JPS52151711A (en) | 1977-12-16 |
| JPS6157289B2 (enrdf_load_stackoverflow) | 1986-12-06 |
| BE853350R (fr) | 1977-10-07 |
| DE2715748A1 (de) | 1977-10-27 |
| FR2347048B2 (enrdf_load_stackoverflow) | 1978-12-15 |
| DE2715748C3 (de) | 1987-06-19 |
| NL7703738A (nl) | 1977-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sgouris et al. | The preparation of human fibrinolysin (plasmin) | |
| Plow et al. | An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. | |
| Ouyang et al. | Purification and properties of the thrombin-like principle of Agkistrodon acutus venom and its comparison with bovine thrombin | |
| Wallén et al. | Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin | |
| Dahlbäck | Human coagluation factor V purification and thrombin-catalyzed activation. | |
| Katayama et al. | Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins. | |
| Markwardt | [69] Hirudin as an inhibitor of thrombin | |
| Markland et al. | Purification and properties of a thrombin-like enzyme from the venom of Crotalus adamanteus (Eastern diamondback rattlesnake) | |
| Duckworth et al. | Purification of insulin-specific protease by affinity chromatography | |
| Kirby et al. | Thrombocytin, a serine protease from Bothrops atrox venom. 1. Purification and characterization of the enzyme | |
| Boissel et al. | Covalent structures of beta and gamma autolytic derivatives of human alpha-thrombin. | |
| Tai et al. | Studies on Limulus amoebocyte lysate II. Purification of the coagulogen and the mechanism of clotting. | |
| US4230691A (en) | Nerve growth factor antibody and process | |
| Wissler | Chemistry and biology of the anaphylatoxin related serum peptide system. I. Purification, crystallization and properties of classical anaphylatoxin from rat serum | |
| Beeckmans et al. | A New Purification Procedure for Fumarase Based of Affinity Chromatography: Isolation and Characterization of Pig‐Liver Fumarase | |
| Seegers et al. | Isolation and some properties of thrombin-E and other prothrombin derivatives | |
| US4407744A (en) | Process for obtaining nerve growth factor | |
| US4185095A (en) | Nerve growth factor | |
| JPH0689014B2 (ja) | トロンビン結合性物質およびその製法 | |
| Harfenist et al. | Degradation of fibrinogen by plasmin. Isolation of an early cleavage product | |
| EP0155852B1 (en) | Thrombin-binding substance and process for its production | |
| Travis et al. | Human pancreatic enzymes. Isolation and properties of a major form of chymotrypsin | |
| US4177262A (en) | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots | |
| DE2734427B2 (de) | Verfahren zur Gewinnung von thrombinartigen Enzymen aus Schlangengiften | |
| GB1581472A (en) | Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed |